Dr. Reddy's Laboratories Ltd.

442 articles about Dr. Reddy's Laboratories Ltd.

• Dr. Reddy's Laboratories Announces the First Generic Launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets in the U.S. Market

  2/27/2020

  Dr. Reddy’s Laboratories Ltd. announced the first-to-market launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, a therapeutic equivalent generic version of Vimovo® Delayed-Release Tablets approved by the U.S. Food and Drug Administration.

• Dr. Reddy’s Laboratories to Acquire Select Business Divisions of Wockhardt in India

  2/12/2020

  Dr. Reddy’s Laboratories Ltd. announced that it has entered into a definitive agreement with Wockhardt Limited to acquire select divisions of its branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives for a consideration of Rs.1850 Crores.

• Dr. Reddy's Laboratories Announces the Launch of Trientine Hydrochloride Capsules USP, 250 mg, in the U.S. Market

  2/7/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Trientine Hydrochloride Capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine® Capsules, approved by the U.S. Food and Drug Administration..

• Dr. Reddy’s Q3 & 9M FY20 Financial Results

  1/27/2020

  Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter ended December 31, 2019 under International Financial Reporting Standards.

• Dr. Reddy's to Release Q3 FY 20 results on January 27, 2020  Earnings Call Slated for January 27, 2020 @ 6:30 PM IST / 8:00 AM EST

  1/10/2020

  Dr. Reddy's Laboratories Ltd. will announce results for the third quarter ended December 31, 2019 on Monday, January 27, 2020 after the Board Meeting..

• Dr. Reddy's Laboratories Announces the Launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL) Single-dose Vial in the U.S. Market

  12/30/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Sodium Nitroprusside Injection, 50 mg/2 mL Single-dose Vial, the therapeutic generic equivalent of Nitropress® Injection, 50 mg/2mL vial, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Deferasirox Tablets for Oral Suspension, in the U.S. Market

  12/6/2019

  Dr. Reddy’s Laboratories Ltd. today announced the launch of Deferasirox Tablets for Oral Suspension, a therapeutically equivalent generic version of Exjade® Tablets for Oral Suspension, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Deferasirox Film-Coated Tablets, in the U.S. Market

  12/6/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Deferasirox Film-Coated Tablets, 90 mg and 360 mg, a therapeutically equivalent generic version of Jadenu® Film-Coated Tablets, 90 mg, 180 mg, and 360 mg, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection 3.5 mg/vial for Intravenous Use Only in the U.S. Market

  12/4/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Bortezomib for Injection 3.5 mg/vial, approved by the U.S. Food and Drug Administration via a 505 new drug application pathway for intravenous use only..

• Dr. Reddy's Laboratories announces launch of Doxercalciferol Injection in the U.S. Market

  11/22/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Doxercalciferol Injection, 4 mcg/2 mL Multiple-Dose Vials, the therapeutic generic equivalent of Hectorol® Injection 4 mcg/2 mL Multiple-Dose Vials, approved by the U.S. Food and Drug Administration..

• Dr. Reddy’s Q2 & H1 FY20 Financial Results

  11/1/2019

  Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter and the half year ended September 30, 2019 under International Financial Reporting Standards.

• Dr. Reddy’s Confirms Its Voluntary Nationwide Recall of All Ranitidine Products in the U.S. Market

  10/23/2019

  Dr. Reddy’s Laboratories Ltd. confirms it had initiated a voluntary nationwide recall on October 1, 2019, of all of its ranitidine medications sold in US due to confirmed contamination with N-Nitrosodimethylamine above levels established by the FDA.

• Dr. Reddy's to release Q2 FY 20 results on November 1, 2019

  10/14/2019

  Dr. Reddy's Laboratories Ltd. will announce results for the second quarter ended September 30, 2019 on Friday, November 1, 2019 after the Board Meeting.

• Dr. Reddy’s Announces the Launch of Over-the-Counter, Store-Brand Equivalent of Prevacid® 24HR Capsules (Lansoprazole Delayed-Release Capsules USP, 15 mg) in the U.S. Market

  9/16/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Lansoprazole Delayed-Release Capsules USP, 15 mg, an over-the-counter (OTC) store-brand equivalent of Prevacid® 24HR Capsules, in the United States market, as approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Announces the Launch of Fosaprepitant for Injection in the U.S. Market

  9/11/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND® (fosaprepitant) for injection, approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Limited to Present at the Morgan Stanley Annual Global Healthcare Conference

  9/6/2019

  Dr. Reddy’s Laboratories Ltd (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) announced that the Company will be presenting at the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10th, 2019, in New York City.

• Dr. Reddy's Laboratories announces the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (SR) in the U.S. Market

  9/5/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (SR), a therapeutically equivalent generic version of Zyban® (Bupropion Hydrochloride) Extended-Release Tablets, approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Powder for Oral Solution, USP in the U.S. Market

  8/20/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Vigabatrin Powder for Oral Solution, USP in 500 mg per packet, a therapeutic equivalent generic version of Sabril® (vigabatrin) Powder for Oral Solution, USP, approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories announces the launch of Versavo® (bevacizumab biosimilar) in India

  8/19/2019

  Dr. Reddy’s Laboratories Ltd. announced that it has launched Versavo®, a biosimilar of Roche’s Avastin® in India, indicated for the treatment of several types of cancers.

• Dr. Reddy's Laboratories announces the launch of Pregabalin Capsules in the U.S. Market

  7/30/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Pregabalin Capsules a therapeutic equivalent generic version of Lyrica® (pregabalin) Capsules approved by the U.S. Food and Drug Administration (USFDA).